Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefuroxime + clarithromycin
- Development stage
- Phase 4
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cefuroxime + clarithromycin is a combination antibiotic therapy used primarily for treating respiratory tract infections, particularly community-acquired pneumonia (CAP). Cefuroxime is a second-generation cephalosporin antibiotic effective against many gram-positive and gram-negative bacteria. Clarithromycin is a macrolide antibiotic effective against atypical pathogens like Mycoplasma pneumoniae and Legionella pneumophila. The combination provides broad-spectrum coverage against common respiratory pathogens including Streptococcus pneumoniae.
02
Targets
Beyond the preview
Go deeper on cefuroxime + clarithromycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefuroxime + clarithromycin.